ONCE - Spark Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
0.00 (0.00%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close113.57
Bid114.48 x 1400
Ask114.48 x 1100
Day's Range113.47 - 113.90
52 Week Range40.64 - 114.20
Avg. Volume602,446
Market Cap4.375B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Spark Therapeutics CEO: 'We get to write the next chapter'
    American City Business Journals

    Spark Therapeutics CEO: 'We get to write the next chapter'

    The co-founder and CEO of Spark Therapeutics called the completion of the company's $4.3B sale to Roche is 'bittersweet.'

  • Roche's Small Spark Deal Holds a Big Regulatory Warning

    Roche's Small Spark Deal Holds a Big Regulatory Warning

    (Bloomberg Opinion) -- Roche Holding AG’s $4.7 billion purchase of gene-therapy developer Spark Therapeutics Inc. finally closed Tuesday after a 10-month regulatory saga. Many industries would shrug at that length of a review period, but it’s an eternity by biotech bolt-on standards.  To the extent it’s a signal of things to come, potential acquirers and targets in this corner of the M&A market should take note — not to mention investors.Roche expected a second-quarter close when it announced the deal in late February. Antitrust authorities made a hash of that timeline as they grew concerned that Roche might stymie Spark’s potentially curative one-time hemophilia treatment to protect its current blockbuster Hemlibra, which treats the same condition. Regulators eventually came to the conclusion that Roche didn’t have much incentive to spike a medicine that it’s paying nearly $5 billion to acquire. It would be easier to dismiss Roche’s troubles if it were the only sign of regulatory wrangling, but this year also brought an unexpected  hiccup for Bristol-Myers Squibb & Co. as it sought to clinch its $74 billion acquisition of Celgene Corp. The Spark holdup confused the market because there are multiple other drugmakers developing hemophilia gene therapies. Investors were equally shocked in June when Bristol-Myers announced a plan to sell Celgene’s psoriasis drug Otezla as part of a deal with the Federal Trade Commission intended to speed the acquisition along. Otezla is a lucrative medicine, but it isn’t dominant. The FTC was worried about the competitive risk to or from a Bristol-Myers pipeline drug, but it’s in a different drug class and is years away from hitting the market. Everything worked out in both of these cases. Bristol-Myers managed to sell Otezla at a reasonable price, while Roche is getting a hold of Spark well before its hemophilia therapy hits the market. The added expense and uncertainty caused by the forced remedy and delay were still damaging, however. Concern that deals that used to be routine might become messy will be more than enough to squash some potential acquisitions. An optimist might see these as one-off delays. Spark and Roche could have just been the unfortunate victims of regulatory unfamiliarity with new technology. The sheer size of the Bristol/Celgene deal may have left the FTC feeling like it needed to do something. A more jaundiced view is probably warranted. If marginal concerns created a 10-month delay for Roche and a $13.4 billion divestiture for Bristol-Myers to resolve, what’s going to happen when there’s a real competitive issue? Biotech M&A isn’t going to screech to a halt, but it is likely to stay more cautious. Investors should adjust target lists and expectations accordingly.To contact the author of this story: Max Nisen at mnisen@bloomberg.netTo contact the editor responsible for this story: Beth Williams at bewilliams@bloomberg.netThis column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.Max Nisen is a Bloomberg Opinion columnist covering biotech, pharma and health care. He previously wrote about management and corporate strategy for Quartz and Business Insider.For more articles like this, please visit us at bloomberg.com/opinion©2019 Bloomberg L.P.

  • Benzinga

    Regulators Give Roche Green Light For $4.3B Spark Therapeutics Acquisition

    Roche Holding (OTCQX: RHHBY ) has received approval from the Federal Trade Commission and Britain’s Competition and Markets Authority to acquire Spark Therapeutics, Inc. (NASDAQ: ONCE ), the companies ...

  • Benzinga

    The Daily Biotech Pulse: Roche Gets US Antitrust Clearance For Spark Purchase, An Orphan Drug Designation For Prevail, Dynavax Names CEO

    The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 16.) Acceleron Pharma Inc (NASDAQ: XLRN ) Amarin ...

  • Roche to complete $4.3 billion Spark deal as regulators give all clear

    Roche to complete $4.3 billion Spark deal as regulators give all clear

    ZURICH/WASHINGTON (Reuters) - Swiss drugmaker Roche plans to complete its $4.3 billion takeover of gene therapy specialist Spark Therapeutics on Tuesday after U.S. and British authorities ruled the deal would not hurt competition in hemophilia A treatment. The Federal Trade Commission (FTC) and Britain's Competition and Markets Authority (CMA) approved the deal on Monday without demanding asset sales. Roche is buying U.S.-based Spark to expand in gene therapy and boost its hemophilia A portfolio, where the Basel-based company's existing drug Hemlibra will surpass $1 billion sales in 2019.

  • Week Begins with Biotech Mergers

    Week Begins with Biotech Mergers

    Week Begins with Biotech Mergers

  • Make it 10: Roche again extends $4.3B bid to buy Spark Therapeutics
    American City Business Journals

    Make it 10: Roche again extends $4.3B bid to buy Spark Therapeutics

    The $114.50 per share tender offer has now been extended 10 times as regulators continue to review the multibillion-dollar gene therapy deal

  • Merger Monday, Biotech Edition: MRK, SNY, ARQL, THOR & More

    Merger Monday, Biotech Edition: MRK, SNY, ARQL, THOR & More

    Large-cap pharmaceutical companies are putting their assets to work in the biotech space, particularly in cancer treatment (oncology).

  • Roche extends tender offer for Spark Therapeutics

    Roche extends tender offer for Spark Therapeutics

    The period for Roche’s offer of $114.50 per share for U.S.-based Spark has been extended several times and was set to expire on Dec. 10.

  • John Paulson's Top 5 Buys in the 3rd Quarter

    John Paulson's Top 5 Buys in the 3rd Quarter

    Merger arbitrage guru releases portfolio Continue reading...

  • Is Spark Therapeutics Inc (ONCE) A Good Stock To Buy?
    Insider Monkey

    Is Spark Therapeutics Inc (ONCE) A Good Stock To Buy?

    Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Our research shows that most of the stocks that smart money likes historically generate strong […]

  • Barrons.com

    Gene-Therapy Firm Audentes Sells for Double Its Share Price. It Could Be the First of Many More Deals.

    Astellas Pharma is paying $60 a share in cash for a gene-therapy stock that closed at $28.61 on Monday.

  • 7 Exciting Biotech Stocks to Buy Now

    7 Exciting Biotech Stocks to Buy Now

    Over the past 12 months, the Nasdaq Biotech Index (NBI) has kept up with the broader market, slightly outpacing the S&P 500, until the last few months.Certainly 2019 has been a bumpy ride. But it looks like the sector, especially thank to its larger firms, is finally hitting its stride. The index is rising and a growing number of mergers over the past couple years are starting to pay off.There are some amazing new technologies that are finally gaining traction on the medication side, which includes a long journey through U.S. Food and Drug Administration trials. It usually takes about 10 years and costs around $2 billion to get a drug through trials these days.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThat's a lot of commitment. And during that time, you need to develop a strong pipeline for future growth. * 7 Entertainment Stocks to Buy to Escape Holiday Blues At Growth Investor, we are focused on pure biotech stocks, not big pharma. These seven big biotech companies are driving cutting-edge therapies. These names are either currently thriving or well positioned for buyouts that would come with big premiums. Biotech Stocks to Buy: Galapagos (GLPG)Source: Shutterstock Galapagos (NASDAQ:GLPG) is a perfect example of the new wave in biotech. It uses adenoviruses -- viruses that usually cause respiratory illnesses -- to introduce human gene sequences to help or prevent certain proteins from multiplying.The formations of proteins play a critical role in a number of diseases, including cancer. They are also key in autoimmune diseases. And GLPG focuses on the latter.It has four drugs in clinical trials currently, and two of those are in Phase 3 trials. That is encouraging, since it is usually moving into Phase 3 trials where many drugs fall short.The stock is up a whopping 94% this year as trial results are driving price, yet its trailing price-to-earnings ratio is 38. It has a $12 billion market capitalization, so it's well funded. China Biologic Products (CBPO)Source: Shutterstock China Biologic Products (NASDAQ:CBPO) is one of China's leading biotech companies. Its work isn't fancy, but it's functional. And in a population of 1.4 billion people, high-quality drugs represent a huge step forward.China is very focused on developing its pharmaceutical and healthcare industry instead of relying on the U.S or Europe to sell it medicines. But this is a huge undertaking to start from nearly scratch.CBPO is one of the first to do it. It's not making cutting-edge drugs and doing breakthrough research -- it's focused on plasma-based biopharmaceutical products. These are fundamental for treatment of immune system disorders, epidemic diseases and disaster relief. * 10 Cheap Stocks to Buy Under $10 It gained a lot of attention last year when a consortium offered nearly $4 billion for the company. Its current market cap is $4.5 billion and the stock is up 54% year-to-date. That's the kind of momentum I like to see at Growth Investor, and there's still plenty of headroom here. Arrowhead Pharmaceuticals (ARWR)Source: Shutterstock Arrowhead Pharmaceuticals (NASDAQ:ARWR) works on novel drugs for intractable diseases. And that about sums up its focus.Right now, it has nine drugs in trials. Two of them are in Phase 3. One is for liver disease and the other for Hepatitis B. Most of its other drugs are focused on diseases affecting the liver. It also has one in trial for lung cancer and another for renal cell carcinoma.It is focused on using RNAi, or RNA interference, to prevent cells from expressing a specific gene, usually a gene linked to a disease. RNAi has been around for a long time, and ARWR has been around since 1989. But it's now coming into its own, as technologies have grown up around it.The stock is up a staggering 432% year-to-date, due to its own work and the interest that big pharma is now taking in the sector. With a $6.3 billion market cap, it would be an easy buy for a big firm looking to acquire a solid pipeline of RNAi drugs. Acadia Pharmaceuticals (ACAD)Source: Shutterstock Acadia Pharmaceuticals (NASDAQ:ACAD) focuses on central nervous system disorders. These range from schizophrenia to Parkinson's to major depressive disorder.It actually has a drug in the market. In 2016 Nuplazid was launched to help manage the hallucinations and disorientation sometimes experienced by Parkinson's patients. Second-quarter sales were $83 million, up 46% from the same quarter a year ago. That's more than $300 million a year, and growing.It has another drug that is wrapping up Phase 3 trials and is targeted at dementia-related psychosis. Yet another drug is halfway through Phase 3 trials focused on providing an adjunctive therapy for major depressive disorder.This firm isn't just about the future, it's succeeding in the market right now. And in a unique niche, no less. This niche will continue to grow as boomers age, so demographics are also on its side. That's the kind of growth potential I demand from stocks in any industry. * 9 Tantalizing Dividend Stocks for 2020 ACAD stock is up 182% year-to-date and with a $7 billion market cap, it's still the early days. Spark Therapeutics (ONCE)Source: Shutterstock Spark Therapeutics (NASDAQ:ONCE) is a gene therapy company that focuses on genetic diseases including blindness, hemophilia and neurodegenerative conditions.These can be good areas for a relatively young gene company to plant its flag, because they aren't usually filled with as much competition. That also means that during drug trials, its efficacies don't have to meet as high standards.ONCE just launched its first drug this year, Luxturna, for inherited retinal dystrophy, which ultimately leads to blindness. Sales and results have been positive. The company also has a licensing and development deal with Pfizer (NYSE:PFE) for a drug targeting hemophilia. And Novartis (NYSE:NVS) has control of European marketing for Luxturna.The stock is up 184% year-to-date and has a bright future if it can keep delivering. Zai Lab (ZLAB)Source: Shutterstock Zai Lab (NASDAQ:ZLAB) is a Chinese biotech that launched in 2014. But today, it has a $2.6 billion market cap. That's some pretty fast growth.Part of the reason is that Incyte Pharmaceuticals (NASDAQ:INCY), maker of the rheumatoid arthritis drug Jakafi, has become an investor. This partnership allows INCY to market its drug in China and gives ZLAB access to the U.S. market. At Growth Investor, we invest with an eye on macroeconomic trends, and these are the two markets exhibiting the strongest growth.Their product lines overlap as well, which has some strategic advantages. Both have products in autoimmune diseases, and ZLAB also is doing work in cancer and infectious diseases.ZLAB has 16 drugs in Phase 3 trials, with one, Optune, ready for market in Hong Kong. Its massive pipeline is especially attractive for a firm like INCY when looking at marketing some of these in the U.S. market. * 7 Top Stocks to Buy for 2020 The stock is up 73% year-to-date and could be a sleeping giant, if all unfolds according to plan. Natera (NTRA)Source: Shutterstock Natera (NASDAQ:NTRA) isn't a typical biotech in the sense that it develops drugs.Its niche is genetic testing. While you may think that begins and ends with prenatal testing for hereditary disorders and the like, the fact is, that's just the beginning.It can run testing on cancers so that oncologists can get an exact description of the cancer. Today, there are gene therapies and immuno-oncology therapies that can be used to help certain cancer patients. And that list is growing. Also, recurrence monitoring and treatment monitoring are much more targeted and accurate.Also, genetic testing can help make sure that transplants are more successful. For insurers and hospitals (as well as patients of course), a clean transplant means no issues with tissue rejection, infection or longer hospital stays.It might not have a sexy silver bullet in this sector, but it does have a great reputation.The stock is up 155% year-to-date. And given the lack of drama in the stock, its big growth could keep on going as long as the population continues to gray.All this gives you an idea of why these stocks rate so highly in my Portfolio Grader tool. And I've got more where that came from. There's a bigger, deeper tech trend going on that I'm even more excited about. 'The Mother of All Technologies'Up until now, technologies have certainly made our lives easier and more efficient … but with a lot of room for human error. People trip over cords, spill their coffee and get tired.Artificial intelligence does not.If that sounds futuristic, well then, the future is already here. If you use apps like Netflix (NASDAQ:NFLX), TurboTax, QuickBooks, Zillow (NASDAQ:Z) or even an email spam filter, then AI is already helping your day run more smoothly. And as scientists find even more applications for artificial intelligence -- from healthcare to retail to self-driving cars -- it's incredible to imagine how much data will be involved.To create AI programs in the first place, tech companies must collect vast amounts of data on human decisions. Data is what powers every AI system.So any one company that can help with customers' data issues is the one company that's most worth investing in.You don't need to be an expert to take part. I'll tell you everything you need to know, as well as my "buy" recommendation, in Growth Investor. My No. 1 stock for the AI trend is still under my buy limit price -- so you'll want to sign up now. Get in while it's still cheap.Click here for a free briefing on this groundbreaking innovation.Louis Navellier had an unconventional start, as a grad student who accidentally built a market-beating stock system -- with returns rivaling even Warren Buffett. In his latest feat, Louis discovered the "Master Key" to profiting from the biggest tech revolution of this (or any) generation. Louis Navellier may hold some of the aforementioned securities in one or more of his newsletters. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Things to Watch for into 2020 for Safer Income & Growth * 7 Entertainment Stocks to Buy to Escape Holiday Blues * 5 "Strong Buy" Biotech Stocks With More Than 80% Upside The post 7 Exciting Biotech Stocks to Buy Now appeared first on InvestorPlace.

  • Roche's $4.3B tender offer for Spark is extended yet again
    American City Business Journals

    Roche's $4.3B tender offer for Spark is extended yet again

    For the ninth time this year, Roche — which back in February entered into an agreement to buy Philadelphia gene therapy pioneer Spark Therapeutics for $4.3 billion — has extended its tender offer to Spark's shareholders. The $114.50 per share tender offer was set to expire at 5 p.m. on Nov. 25. As of Nov. 21, about 5.7 million shares of Spark — representing 14.8% of the company's outstanding shares — had been validly tendered and received.

  • BioMarin Files MAA to EMA for Gene Therapy of Hemophilia A

    BioMarin Files MAA to EMA for Gene Therapy of Hemophilia A

    BioMarin (BMRN) submits an MAA in Europe for its investigational gene therapy valoctocogene roxaparvovec to treat adult patients with severe hemophilia A.

  • Investors Hope for More From Takeda Than a Healthy Dividend

    Investors Hope for More From Takeda Than a Healthy Dividend

    The company is in early stages of testing gene and cell therapies they hope will deliver 'transformative and curative' treatments Continue reading...

  • Biogen Ends Enrollment in Eye Disorder Study on Gene Therapy

    Biogen Ends Enrollment in Eye Disorder Study on Gene Therapy

    Biogen (BIIB) completes enrollment in the global phase III STAR clinical study evaluating the gene therapy timrepigene emparvovec for the treatment of a rare, inherited retinal disorder.

  • Reuters

    Roche extends offer deadline for Spark Therapeutics again

    Roche has again extended the deadline for its tender offer for Spark Therapeutics , the Swiss drugmaker said on Friday, saying U.S. and British anti-trust authorities needed more time to review the deal. All terms and conditions of the offer remain the same, Roche said. Roche has put back the deadline several times since it announced the $4.3 billion offer to buy the gene therapy company in February.

  • 7 Philadelphia-area companies make Deloitte fastest-growing list
    American City Business Journals

    7 Philadelphia-area companies make Deloitte fastest-growing list

    Seven Philadelphia-area companies made the list of Deloitte’s fastest-growing tech companies.  Deloitte's latestTechnology Fast 500 ranks the fastest-growing technology companies in North America.

  • For the eighth time, Roche extends $4.3B tender offer for Spark Therapeutics
    American City Business Journals

    For the eighth time, Roche extends $4.3B tender offer for Spark Therapeutics

    Roche on Tuesday once again extended its tender offer to Spark Therapeutics shareholders, citing a need to give regulators additional time to review Roche's proposed $4.3 billion acquisition of the Philadelphia gene therapy pioneer. This is the eighth extension of the tender offer deadline. In February, the two companies announced a merger deal under which Roche would pay Spark stockholders $114.50 per share.

  • Will Spark Therapeutics (ONCE) Report Negative Q3 Earnings? What You Should Know

    Will Spark Therapeutics (ONCE) Report Negative Q3 Earnings? What You Should Know

    Spark Therapeutics (ONCE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Why Roche's Acquisition Of Spark May Be Complete By Year's End
    Investor's Business Daily

    Why Roche's Acquisition Of Spark May Be Complete By Year's End

    Roche's acquisition of Spark will likely close before year's end, an analyst said after reports suggested U.S. regulators would bless the deal. Next, U.K. regulators will consider the deal.

  • FTC staff recommends approval of Roche deal for Spark: report

    FTC staff recommends approval of Roche deal for Spark: report

    The Federal Trade Commission staff reviewing Roche's plan to buy U.S.-based gene therapy specialist Spark Therapeutics for $4.3 billion recommended that the deal be approved without requiring any asset sales, the Capitol Forum reported on Thursday. Basel-based Roche, the biggest maker of cancer drugs, said in February that it would buy the U.S. company, acquiring a portfolio that includes a blindness treatment that has U.S. and European approval and other projects for neurodegenerative disorders like Huntington's disease. One of its projects is a gene therapy treatment for hemophilia.